

CME Session 1

Oncology & Theranostics Committee

Sunday, October 16, 08:00-09:30

Session Title

Radionuclide Therapies - Controversies and Special Considerations

Chairpersons

Sona Balogova (Bratislava, Slovakia)

Mike Sathekge (Pretoria, South Africa)

Programme

08:00 - 08:20 **Luca Giovannella** (Bellinzona, Switzerland): Thyroid Cancer - Controversies and Special Considerations in Therapy using ¹³¹I

08:20 - 08:45 **Irene Virgolini** (Innsbruck, Austria): Neuroendocrine Tumours - Controversies and Special Considerations in [¹⁷⁷Lu]Lu-DOTATATE Therapy

08:45 - 09:10 **Archie Agrawal** (Mumbai, India): Prostate Cancer - Controversies and Special Considerations in [¹⁷⁷Lu]Lu-PSMA Therapy

09:10 - 09:30 **Manuel Weber** (Essen, Germany): HCC and Liver metastases - Controversies and Special Considerations in Selective Internal Radiation Therapy (SIRT)

Educational Objectives

1. Current evidence, trends, and controversies in Radionuclide therapy in specific cancer types (e.g. Neuroendocrine tumours, prostate cancer, thyroid cancer, hepatocellular cancer and liver metastases)
2. Special considerations in management of common technical & clinical challenges in the implementation and delivery of radionuclide therapies (e.g. in ¹⁷⁷Lu-DOTATATE, ¹⁷⁷Lu-PSMA, ²²⁵Ac-PSMA, ¹³¹I, SIRT)
3. Practical solutions to deal with special clinical scenarios.

Summary

In most cases, patient selection for radionuclide therapies is straightforward based on established guidelines. In general, radionuclide therapies are often well tolerated. However, patients referred to radionuclide therapies often have co-morbidities deranged biochemical parameters. The risk-benefit analysis needs to be evaluated to limit any risks associated with radionuclide therapies in these scenarios. For patients with risk factors for complications or who have previously had difficulties, care needs to be taken in deciding the appropriateness of radionuclide therapies. The challenges could be clinical or technical. Therefore, patients with high-risk scenarios should ideally be discussed in detail at multidisciplinary meetings to provide the best clinical care. The faculty will systematically share their experience and discuss the current evidence, trends, success, and challenges related to radionuclide therapies.

Key Words

Radionuclide therapies, ¹⁷⁷Lu-DOTATATE, ¹⁷⁷Lu-PSMA, ²²⁵Ac-PSMA, ¹³¹I, SIRT